Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal fractional mRNA SARS-CoV-2 vaccination in adults with fibrodysplasia ossificans progressiva
NL-OMON58881Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bretovameran in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoints: Systemic safety events, SARS-CoV-2 wild-type neutralising antibody titres and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
bretovameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON58881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58881.